Delayed angioedema after administration of the severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine
The coronavirus disease 2019 (COVID-19) pandemic has led to millions of deaths worldwide and continues to be a public health threat. Administration of COVID-19 vaccines safely and markedly decreases the chance of contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevents severe COVID-19. Their widespread use is imperative to ending the pandemic. Since their implementation, various adverse reactions to the messenger RNA (mRNA) COVID-19 vaccines have been reported, with the most common being delayed cutaneous reactions, and, rarely, anaphylaxis.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Melissa M. Watts, Laura E. Maurer, Leslie C. Grammer, Carol A. Saltoun, Whitney W. Stevens Tags: Letters Source Type: research
More News: Allergy | Allergy & Immunology | Anaphylactic Shock | Asthma | Coronavirus | COVID-19 | International Medicine & Public Health | Pandemics | Respiratory Medicine | SARS | Vaccines